La cadena de opciones muestra datos clave de las opciones de acciones de Biodexa Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Biodexa Pharmaceuticals..

Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa, Cadena de Opciones

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Mercados

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BDRX

DECK

HNRG

IMMX

INEO

INTU

LITM

LTBR

MLGO

MNSO

OKLO

ROST

SGBX

SOBR

VTAK

Intuit sorprende al mercado con ingresos y BPA mejores de lo esperado. Revisa los mayores ganadores y perdedores del premercado.

Las acciones de Intuit (INTU) cotizan un 8% más alto; Aquí están 20 acciones que se mueven en el premercado

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Press Releases

Results of Annual General Meeting

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP)

ADR Ratio Change

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change Effective

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial  in Familial Adenomatous Polyposis (FAP)

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Interim results for the six months ended June 30, 2025

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Aditxt

AIM ImmunoTech

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

BriaCell Therapeutics

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Genprex

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Medicus Pharma

Oragenics

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Ladenburg Thalmann

Screenshot 2025-09-08 at 3.59.27 PM

Biotech

General

RXRX

Tempest Therapeutics, Inc. - Common Stock

TPST

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled

BDRX-logo

PVLA

How Biodexa Is Racing To Get Its Phase 3 Program In FAP Under Way And Gain First-Mover Advantage In A $7B Addressable Market

Screenshot 2025-06-17 at 8.31.13 PM

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Screenshot 2025-03-18 at 8.36.36 PM

Fast Track Designation Secured, Successful Protocol Discussion With FDA And CROs Confirmed, Biodexa On Track To Initiate Funded Phase 3 FAP Trial Next Quarter

Untitled design - 2025-02-11T232646.924

Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa&#39;s FAP Drug Receives FDA Fast Track Status

Image

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic

Untitled design - 2024-10-16T235234.675

Biodexa&#39;s MX-110 Continues To Show Promise In Recurrent Glioblastoma (rGBM), The Deadliest Brain Cancer

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Comments

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals (BDRX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL